Genmab categorically refutes allegations and will vigorously defend the company ...

Absci Corp. (($ABSI)) has held its Q4 earnings call. Read on for the main highlights of the call. Absci Corp’s recent earnings call presented a ...

The country is also advancing the integration of TCM into modern healthcare by optimizing its clinical use and expanding ...

The company stated that although it has dropped vobra duo, it remains optimistic about its other candidate MGC026.

The Microbiome Disease Pipeline Report 2025 reveals 180+ drugs under development across 140+ companies, covering late-stage, mid-stage, and early-stage therapies. Major players such as MaaT Pharma, ...

Find insight on BioNTech, PharmAla Biotech, Dentalcorp Holding and more in the latest Market Talks covering the Health Care ...

However, for the Company, 2024 was both a “year of restructuring” amidst challenges and a “year of breakthroughs” with emerging potentials. Although the overall performance is experiencing short-term ...

Sino Biopharm has a good financial position. As of December 2024, it has CNY 9.6 billion in cash on hand and CNY 9.6 billion in debt. Total debt outstanding is 14.7% of its total assets. Its capital ...

Discover why Gyre Therapeutics is rated 'Hold' amid volatile stock behavior, uncertain long-term prospects, and pending Phase ...

Innate Pharma continues its slow rollout of promising clinical candidates, with 2025 set for key milestones. Read more about ...

Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for ...

Police severed a drug pipeline with the arrest of four people, including a married couple, who were caught on suspicion of ...